Table 1.
Characteristics of the Participants at Baseline.
| Characteristic | Participants (N = 150) |
|---|---|
| Age | |
| Mean (range) — yr | 37.8 (<1 to 83) |
| Age group — no. (%) | |
| 0–17 yr | 17 (11.3) |
| 18–64 yr | 124 (82.7) |
| ≥65 yr | 9 (6.0) |
| Female sex — no. (%) | 66 (44.0) |
| Pregnancy — no. (%) | 5 (3.3) |
| Presence of signs or symptoms of Zika virus infection at enrollment — no. (%) | |
| No* | 4 (2.7) |
| Yes | 146 (97.3) |
| Days after symptom onset at enrollment — no./total no. (%) | |
| 0–2 days | 66/146 (45.2) |
| 3–5 days | 63/146 (43.2) |
| 6–7 days | 5/146 (3.4) |
| 8–14 days | 4/146 (2.7) |
| ≥15 days | 8/146 (5.5) |
| Signs or symptoms at enrollment — no./total no. (%)† | |
| Fever | 115/146 (78.8) |
| Red eyes or eye pain | 119/146 (81.5) |
| Rash | 135/144 (93.8) |
| Pruritus | 117/145 (80.7) |
| Photophobia | 59/144 (41.0) |
| Edema | 92/145 (63.4) |
| Arthralgia | 120/139 (86.3) |
| Myalgia | 102/125 (81.6) |
| Headache | 115/145 (79.3) |
| Abdominal pain | 73/145 (50.3) |
| Lymphadenopathy | 50/144 (34.7) |
| Diarrhea | 62/145 (42.8) |
| Nausea | 63/145 (43.4) |
| Vomiting | 17/145 (11.7) |
| Pelvic pain | 25/139 (18.0) |
| Dysuria | 25/145 (17.2) |
| Other‡ | 129/144 (89.6) |
| Laboratory findings | |
| Median white-cell count (range) per mm3 | 5200 (2100 to 40,000) |
| Median platelet count (range) per mm3 | 216,000 (80,000 to 373,000) |
| Median hematocrit (range) — % | 42.2 (30.9 to 51.9) |
*
This category includes two participants who were asymptomatic at baseline but in whom signs or symptoms developed within 7 days after specimen collection.
†
The median duration of fever was 2 days (range, 1 to 22); red eyes, 3 days (range, 1 to 7); and rash, 5 days (range, 1 to 25).
‡
Other signs or symptoms included cough (in 33.1% of the participants), yellow eyes or skin (4.8%), difficulty urinating (7.8%), blood in urine (5.5%), painful ejaculation (6.7% of men), and penile discharge (2.7% of men).